Deals channel feed – Endpoints News

Deals channel feed

Bristol Myers fronts new Schrödinger alliance with $55M upfront, expanding precision oncology profile

5 years ago

In final days at Merck, Roger Perlmutter bets big on a little-known Covid-19 treatment

5 years ago

In an apparent R&D about-face, Eli Lilly partners with Precision BioSciences on genome editing in a deal worth up to nearly $2.7B

5 years ago

AstraZeneca, Samsung quit race to develop Rituxan copycat as rivals crowd out the market

5 years ago

Novartis bags Mesoblast's stem cell therapy for ARDS, including in Covid-19, in a deal worth up to $1.2B+

5 years ago

Eli Lilly's Covid-19 partner AbCellera pays $90M for some very special mice as Peter Thiel jumps on the board and IPO rumors heat up

5 years ago

Pfizer hands LianBio $70M to tag along Perceptive's China play, with an eye to beefing up regional portfolio

5 years ago

Renegotiate the $6B CVR deal Bristol Myers made for the Celgene buyout? Caforio says that’s not happening

5 years ago

Roche inks $308.6M collaboration deal with Lead Pharma, focusing on immune-mediated disease

5 years ago

An ex-Vant further immerses itself in a new umbrella, cashing out in a $584M M&A deal with Sumitomo Dainippon subsidiary

5 years ago

No thanks: Roche backs out of EGFR-related protein degraders in revised deal with C4

5 years ago

UCB is beefing up its gene therapy ops with back-to-back deals to buy a startup and sign up a university spinout for discovery work

5 years ago

Citing toxicity concerns, Boehringer Ingelheim drops short-lived IPF pact — keeping $1B+ in its pocket

5 years ago

Vivek Ramaswamy eyes an I/O vant with up to $2B licensing deal

5 years ago

Novo Nordisk bolts on a ‘holy grail’ oral delivery platform in $1.8B buyout

5 years ago

What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on

5 years ago

Inspired by ASH data, Merck's Roger Perlmutter swoops in with a $2.75B ROR1 buyout aimed at beefing up the cancer pipeline

5 years ago

Eyeing commercialization, a Shanghai-based CAR-T startup nabs a $186M megaround

5 years ago

Sana Biotechnology snags Oscine, adding cell therapy leader Steve Goldman to its star-studded staff

5 years ago

PerkinElmer buys out British gene editing player for $383M, boosting its diagnostics and genomic capabilites

5 years ago

Royalty Pharma tops its record-setting $3.3B deal with CF Foundation, betting $575M more on Vertex's drugs

5 years ago

Joe Jimenez has one more thing to do in biopharma. And now he and Mark Fishman have a $133M stake to play the startup game

5 years ago

AstraZeneca sells off heart failure and hypertension drugs to Cheplapharm for $400M

5 years ago

Arcus and AstraZeneca partner on a high stakes anti-TIGIT/PD-L1 PhIII cancer study, looking to improve on a standard of care

5 years ago

First page Previous page 84 85 868788 89 90 Next page Last page